vations to life
Our ApproachOur partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products we help develop.
Our PipelineOur pipeline is comprised of innovative therapeutic products that have the potential for optimized value creation using our partnership-enabled business model.
Our PeopleWe are led by a highly accomplished, multidisciplinary management team and board of directors with extensive experience in all phases of therapeutic device development.
Our two late-stage flagship products are designed to address large unmet needs associated with the treatment of atherosclerotic artery disease, the leading cause of death worldwide, and hypertension, the leading contributing risk factor for morbidity and mortality worldwide.
Virtue SAB is a patented drug/device combination product for the treatment of artery disease that delivers a proprietary extended release formulation of sirolimus, SirolimusEFR, during balloon angioplasty without the need for a coating or a permanent implant.
BackBeat CNT™ is a patented bioelectronic treatment for hypertension that is designed to drive an immediate, substantial and persistent reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain lowered blood pressure long-term.
